WEST PHARM.SVCS DL-,25/ US9553061055 /
| 2024-11-14 8:01:53 AM | Chg. +17.5000 | Volume | Bid10:00:01 AM | Ask10:00:01 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 323.5000EUR | +5.72% | 0 Turnover: 0.0000 |
324.1000Bid Size: 20 | 329.0000Ask Size: 20 | 23.59 bill.EUR | - | - |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 839.3000 | 943.2000 | 1,057.5000 | 1,158.3000 | 1,413.3000 | ||||||
| Intangible Assets | 29.8000 | 30.5000 | 23 | 18.4000 | 15.1000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 1,282.7000 | 1,420.1000 | 1,571.8000 | 1,697.3000 | 1,893.1000 | ||||||
| Inventories | 235.7000 | 321.3000 | 378.4000 | 414.8000 | 434.7000 | ||||||
| Accounts Receivable | 319.3000 | 385.3000 | 489 | 507.4000 | 512 | ||||||
| Cash and Cash Equivalents | 439.1000 | 615.5000 | 762.6000 | 894.3000 | 853.9000 | ||||||
| Current Assets | 1,058.7000 | 1,373.7000 | 1,742 | 1,919.5000 | 1,936.4000 | ||||||
| Total Assets | 2,341.4000 | 2,793.8000 | 3,313.8000 | 3,616.8000 | 3,829.5000 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 156.8000 | 213.1000 | 232.2000 | 215.4000 | 242.4000 | ||||||
| Long-term debt | 255 | 252.9000 | 208.8000 | 206.7000 | 72.8000 | ||||||
| Liabilities to Banks | 2.3000 | - | - | - | - | ||||||
| Provisions | 21.9000 | - | - | - | - | ||||||
| Liabilities | 768.2000 | 939.3000 | 978.4000 | 931.9000 | 948.5000 | ||||||
| Share Capital | 18.8000 | 18.8000 | 18.8000 | 18.8000 | 18.8000 | ||||||
| Total Equity | 1,573.2000 | 1,854.5000 | 2,335.4000 | 2,684.9000 | 2,881 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,341.4000 | 2,793.8000 | 3,313.8000 | 3,616.8000 | 3,829.5000 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,839.9000 | 2,146.9000 | 2,831.6000 | 2,886.9000 | 2,949.8000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 296.6000 | 406.9000 | 752.3000 | 734 | 676 | ||||||
| Interest Income | 8.5000 | 8.2000 | 8.2000 | 7.9000 | 9 | ||||||
| Income Before Taxes | 291.8000 | 401.3000 | 748.9000 | 679.9000 | 698 | ||||||
| Income Taxes | 59 | 72.5000 | 107.2000 | 114.7000 | 122.3000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 241.7000 | 346.2000 | 661.8000 | 585.9000 | 593.4000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 367.2000 | 472.5000 | 584 | 724 | 776.5000 | ||||||
| Cash Flow from Investing Activities | -228 | -179.5000 | -253.1000 | -288.2000 | -368.7000 | ||||||
| Cash Flow from Financing | -36.8000 | -137.1000 | -168.1000 | -293.6000 | -459.6000 | ||||||
| Decrease / Increase in Cash | 101.7000 | 176.4000 | 147.1000 | 131.7000 | -40.4000 | ||||||
| Employees | 8,200 | - | - | - | - | ||||||
